takinib

Description: Takinib is a novel, potent and selective TAK1 inhibitor with an IC50 of 9.5 nM. Takinib induces apoptosis following TNF-alpha stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. Takinib is an inhibitor of autophosphorylated and non-phosphorylated TAK1 that binds within the ATP-binding pocket and inhibits by slowing down the rate-limiting step of TAK1 activation. Overall, Takinib is an attractive starting point for the development of inhibitors that sensitize cells to TNF-alpha-induced cell death, with general implications for cancer and autoimmune disease treatment. Tumor necrosis factor alpha (TNF-alpha) has both positive and negative roles in human disease. In certain cancers, TNF-alpha is infused locally to promote tumor regression, but dose-limiting inflammatory effects limit broader utility. In autoimmune disease, anti-TNF-alpha antibodies control inflammation in most patients, but these benefits are offset during chronic treatment. TAK1 acts as a key mediator between survival and cell death in TNF-alpha-mediated signaling.

References: Cell Chem Biol. 2017 Aug 17; 24(8):1029-1039.